James Gruber
Director of Finance/CFO at ETON PHARMACEUTICALS, INC.
Net worth: 13 496 $ as of 2024-03-30
Profile
James R.
Gruber is currently the Chief Financial Officer, Secretary & Treasurer at Eton Pharmaceuticals, Inc. He previously worked as the Vice President & Controller at Horizon Therapeutics, Inc. Gruber received an undergraduate degree from Indiana University and an MBA from Kellogg School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-12 | 3,599 ( 0.01% ) | 13 496 $ | 2024-03-30 |
James Gruber active positions
| Companies | Position | Start |
|---|---|---|
| ETON PHARMACEUTICALS, INC. | Director of Finance/CFO | 2022-04-10 |
Former positions of James Gruber
| Companies | Position | End |
|---|---|---|
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Comptroller/Controller/Auditor | - |
Training of James Gruber
| Indiana University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ETON PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
- Stock Market
- Insiders
- James Gruber
